Matched Conjugation Platforms Unlock the Therapeutic Potential of Heterobifunctional Degrader-Antibody Conjugates Through mAb-like Pharmacokinetics at High DAR and Excellent In Vivo Efficacy
- Payloads of current marketed ADC are limited to three Modes of Action (MoAs): DNA binders, Tubulin- and TOP-I-Inhibitors
- Here we present novel conjugation technologies for stable conjugation and traceless release of heterobifunctional degraders
- Resulting DACs are homogenous with high DAR, have excellent linker stability, and exhibit unprecedented in vivo PK and efficacy